Clinical Trial Update: Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study [Phase 2]

View source ↗

Summary

Phase 2 TaZA CLL study evaluating the combination of tafasitamab and zanubrutinib for newly diagnosed chronic lymphocytic leukemia or small lymphocytic lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• Monjuvi (tafasitamab) (tafasitamab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING